CDR2 and cancer: If the patient had a nonclassical syndrome, then a well-characterized onconeuronal antibody, such as anti-Hu, Yo, CV2, Ri, MA2, or amphiphysin, with the diagnosis of cancer within five years of development of neurological symptoms was also sufficient for diagnosis.